The Risk of recurrence in prostate cancer
by: Fritz Frei
Prostate cancer disease
Prostate cancer - the most common form of cancer in men is Prostate cancer, the second leading cause of cancer death. The Main risk factors include age (incidence increases in men over the age of 65 years). It is more prevalent in the western world and about 10% of cases can be linked to family history. The recurrance Rate of the prostate cancer is high.
Mostly, the Prostate cancer is a continuum; progressing through localized, locally advanced, advanced and hormone-refractory stages In general it is a slow growing cancer. He is primarily under hormonal control i.e. testosterone. The choice of treatments which include watchful waiting, surgery (prostatectomy), radiotherapy, hormonal therapy and chemotherapy are dependent on the stage of disease.
1. Most important, that If detected early, using PSA determination, DRE examination and biopsies, and treated appropriately, survival rates are excellent.
2. The most critical focus for the treatment of prostate cancer is to treat those cancers where it is necessary.
3. The Decisions about the best management of prostate cancer can be very complex and depend upon the:
- Pathology of the cancer (unlike other cancers, prostate cancer often progresses very slowly)
- The impact that treatment can have on quality of life, including sexual activity
- Stage of the disease (non-metastatic (localized or locally advanced), metastatic or hormone refractory)
- Age and general health of the patients at diagnosis
- Patient’s preference for treatment
- PSA at diagnosis
4. The treatment options for prostate cancer are:
- Deferred treatment often called ‘watchful waiting’ or 'active surveillance'
- Surgery – Radical Prostatectomy
- Radiotherapy – External Beam and/or Brachytherapy
-Hormonal (endocrine) therapy – Androgen Ablation e.g. anti-androgens, medical castration (LHRHa) or surgical castration
- Palliative Therapy e.g. chemotherapy
- Investigational Therapies
Prostate Cancer Recurrence Rates ***
Prostate cancer is now detected at earlier stages due to heightened awareness and improved screening techniques. Despite definitive therapy, cancer cells may remain and can go undetected for years until they develop into metastatic disease. The risk of recurrence is high, suggesting there is a need to improve treatment approaches. Therefore, it is important to predict pathological stage and risk of disease recurrence early, so that appropriate treatment and/or monitoring can be initiated. The result's of all new treatments will bring us in the future the chance of a lower prostate recurrance.
**You can inform you about the recurrence Rates on:
This gives you an overview with a study case – and the results.
Latest Cancer News:
Cancer teen hits £1m charity target
A teenage blogger with terminal cancer raises more than £1m for charity after posting his final message to followers. Cancer Care Ontario finds thousands of cancer cases caused by alcohol consumption
Ontarians unaware of the cancer risks associated with drinking TORONTO, April 22, 2014 /CNW/ - As many as 3,000 new cancer cases each year in Ontario can be attributed to alcohol consumption, according to a report released today by Cancer Care Ontario (CCO). The report, entitled Cancer Risk Factors in Ontario: Alcohol, is part of a series that examines cancer risk factors facing Ontarians. "Many ... Scientists identify cancer specific cell for potential treatment of gastric cancer
( National University of Singapore ) A team of scientists led by a researcher from the Cancer Science Institute of Singapore at the National University of Singapore has identified the cancer specific stem cell which causes gastric cancer. This discovery opens up the possibility of developing new drugs for the treatment of this disease and other types of cancers. Cancer Treatment: How 'Dustman' Proteins Can Sweep Up Cancerous Cells
Cancer researchers have discovered a new 'dustman' role for a molecule that helps a drug kill cancer cells. The new findings point to a possible test that could identify patients who would be most responsive to a new class of cancer drugs and also those who might develop resistance, as well as suggesting new approaches to discovering more effective drugs. The study, by Cancer Research UK-funded ... Breast cancer drug Kadcyla 'too expensive' for NHS
A BREAST cancer drug currently being tested at a local hospital has been rejected for NHS funding - because it costs too much. Kadcyla, an antibody drug conjugate made by pharmaceutical company Roche, is estimated to give some patients with advanced cancers another six months of life and help to cut the risk of the illness returning. University Hospital of North Staffordshire (UHNS) became the ... Bone Cancer Global Clinical Trials Review, H1, 2014
LONDON, April 22, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Bone Cancer Global Clinical Trials Review, H1, 2014 http://www.reportbuyer.com/pharma_healthcare/drug_discovery/bone_cancer_global_clinical_trials_review_h1_2014.html ... Medline to Deliver Significant Savings as Cancer Treatment Centers of America?s New Prime Vendor Medical Supply ...
Cancer Treatment Centers of America® , a leading provider of innovative cancer care for patients living with complex and advanced-stage disease, recently selected Medline Industries, Inc. Breast cancer drug is too expensive for the NHS: Nice
A breast cancer drug that can extend life by almost six months has been turned down for use on the NHS because it is too expensive. Scientists Identify Cancer Specific Cell for Potential Targeted Treatment of Gastric Cancer
A team of scientists led by a researcher from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has identified the cancer specific stem cell which causes gastric cancer. This discovery opens up the possibility of developing new drugs for the treatment of this disease and other types of cancers. Breast Cancer Drug Blocked By Health Watchdog, Deemed Too Expensive For NHS
A new Herceptin-style breast cancer drug, which costs £90,000 but can prolong lives by almost six months is to be turned down from routine NHS access under draft guidance issued by a health watchdog. Kadcyla is being criticised as "not effective enough" to justify the cost to the NHS, according to the National Institute for Health and Care Excellence (Nice). The watchdog, responsible for ... Breast cancer drug turned down for NHS use due to high cost - The Guardian